Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study
Autor: | Phillip Adams, Jorge L. Armenteros, Magda Campbell, Richard P. Malone, Zena Eisenberg, John E. Overall |
---|---|
Rok vydání: | 1997 |
Předmět: |
Male
medicine.medical_specialty Longitudinal study Pediatrics Dyskinesia Drug-Induced Neurological disorder Tardive dyskinesia Developmental and Educational Psychology medicine Haloperidol Humans Longitudinal Studies Prospective Studies Autistic Disorder Prospective cohort study Child Cumulative dose Incidence (epidemiology) medicine.disease Surgery Psychiatry and Mental health Dyskinesia Child Preschool Female medicine.symptom Psychology medicine.drug Antipsychotic Agents |
Zdroj: | Journal of the American Academy of Child and Adolescent Psychiatry. 36(6) |
ISSN: | 0890-8567 |
Popis: | Objective To report results from a long-term prospective study of safety of haloperidol treatment and prevalence of haloperidol-related dyskinesias. Method Subjects were children with autism requiring pharmacotherapy for target symptoms. After baseline assessments, children received haloperidol treatment; responders requiring further treatment were considered for enrollment into the present study. Six-month haloperidol treatment periods were followed by a 4-week placebo period. The procedure was repeated if further haloperidol treatment was required. At specified times children were evaluated by using multiple instruments. Results Between 1979 and 1994, 118 children aged 2.3 to 8.2 years participated in the study. The mean dose of haloperidol was 1.75 mg/day. Mainly withdrawal dyskinesias (WD) developed in 40 (33.9%) children; 20 had more than one dyskinetic episode. A subgroup that remained significantly longer in the study and had a significantly higher cumulative dose of haloperidol evidenced a significantly higher incidence of WD. Occurrence rates of tardive dyskinesia (TD) and multiple episodes of TD/WD were higher among girls. Conclusion Female gender and pre- and perinatal complications may be involved in susceptibility to dyskinesias; greater cumulative haloperidol dose and/or longer exposure to haloperidol may increase the risk. |
Databáze: | OpenAIRE |
Externí odkaz: |